10-Q: Helix Acquisition Corp. II Reports Q1 2025 Results, Net Loss Incurred Amidst Proposed Business Combination with BridgeBio Oncology Therapeutics

Helix Acquisition Corp. II reports a net loss for Q1 2025 as it progresses towards a proposed business combination with BridgeBio Oncology Therapeutics.

Summary

• Helix Acquisition Corp. II, a special purpose acquisition company (SPAC), filed its Form 10-Q for the quarter ended March 31, 2025.
• The company reported a net loss of $487,392 for the quarter, compared to a net income of $1,100,442 for the same period in 2024.
• General and administrative expenses increased significantly to $2,421,186 from $66,701 in the prior year.
• Interest earned on marketable securities held in the Trust Account was $1,989,268.
• As of March 31, 2025, the Trust Account held $194,438,559 in marketable securities.
• The company is pursuing a business combination with TheRas, Inc. (dba BridgeBio Oncology Therapeutics), with an agreement signed on February 28, 2025.
• The proposed transaction includes domestication of Helix Acquisition Corp. II to Delaware and a merger with a subsidiary of Helix.
• The company has identified a going concern issue, as it lacks the liquidity to sustain operations for a reasonable period and may be forced to liquidate if a business combination is not completed by February 14, 2026.
• Subscription agreements have been entered into with PIPE investors for approximately $260,000,000 of PubCo Common Stock.
• Non-redemption agreements are in place with certain shareholders covering 450,900 Class A ordinary shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is progressing with a business combination, it faces a going concern issue and reported a net loss for the quarter. The PIPE financing and non-redemption agreements are positive developments, but the overall outlook is uncertain.

Positives

• The company has secured subscription agreements for $260,000,000 of PubCo Common Stock with PIPE investors, including $75,000,000 from Cormorant Funds.
• Non-redemption agreements are in place with certain shareholders covering 450,900 Class A ordinary shares, reducing potential redemptions.
• The Trust Account continues to generate interest income, with $1,989,268 earned on marketable securities during the quarter.
• The company has a business combination agreement in place with BridgeBio Oncology Therapeutics.

Negatives

• The company reported a net loss of $487,392 for the quarter ended March 31, 2025, a significant decrease compared to the net income of $1,100,442 for the same period in 2024.
• General and administrative expenses increased substantially to $2,421,186, impacting profitability.
• The company has a working capital deficit of $631,351 as of March 31, 2025.
• The company has identified a going concern issue, as it lacks the liquidity to sustain operations for a reasonable period.

Risks

• The company faces a going concern issue if it cannot complete a business combination by February 14, 2026, potentially leading to liquidation.
• The consummation of the business combination with BBOT is subject to customary closing conditions, including shareholder approval and the availability of a minimum amount of aggregate transaction proceeds.
• Failure to maintain the listing of PubCo Common Stock on the Nasdaq could jeopardize the business combination.
• Economic uncertainty, trade disputes, and military conflicts could adversely impact the target business and the ability to complete the initial business combination.
• If the Company Closing Cash is less than $400,000,000, the Sponsor will forfeit a number of shares of PubCo Common Stock.

Future Outlook

The company intends to complete a business combination, with a focus on healthcare and healthcare-related industries, and expects to incur significant costs in pursuit of its acquisition plans. If the company is unable to complete an initial Business Combination by February 14, 2026, then the company will cease all operations except for the purpose of liquidating.

Management Comments

• Management has determined that the Company currently lacks the liquidity it needs to sustain operations for a reasonable period of time.
• Management plans to consummate an initial Business Combination prior to the mandatory liquidation date.

Industry Context

The announcement reflects the challenges and risks inherent in the SPAC structure, particularly the pressure to complete a business combination within a specified timeframe and the potential for significant redemptions by public shareholders. The company's focus on the healthcare sector aligns with ongoing investor interest in the industry, but the increased competition for target companies and the need to secure PIPE financing add complexity to the process.

Comparison to Industry Standards

• The increase in general and administrative expenses is not uncommon for SPACs as they progress towards a business combination, reflecting higher legal, financial, and due diligence costs.
• The reliance on PIPE financing to supplement Trust Account proceeds is a common strategy among SPACs, particularly in cases where significant redemptions are anticipated.
• The going concern warning highlights the importance of completing a business combination within the allotted timeframe, a challenge faced by many SPACs.
• Comparable companies in the SPAC market often face similar challenges related to liquidity, redemptions, and the need to secure additional financing.

Management Changes

Related Party Transactions

• The company pays the Sponsor $6,458 per month for office space, utilities, and administrative support services.
• The Sponsor transferred 30,000 Founder Shares to Albert A. Holman, III in connection with his appointment to the board of directors.

Stakeholder Impact

• Shareholders face the risk of liquidation if the business combination is not completed by February 14, 2026.
• Shareholders have the opportunity to participate in the business combination with BBOT and potentially benefit from the future performance of the combined company.
• The Sponsor has agreed to certain forfeiture and lock-up provisions, aligning their interests with those of other shareholders.
• The company's ability to complete the business combination will impact the value of the Public Shares and Private Placement Shares.

Next Steps

• The company needs to obtain shareholder approval for the business combination with BBOT.
• The company must complete the domestication process to Delaware.
• The company needs to satisfy all closing conditions for the business combination, including securing the minimum aggregate transaction proceeds.
• The company must secure the listing of PubCo Common Stock on the Nasdaq Stock Market LLC.

Key Dates

Keywords

business combination, SPAC, BridgeBio Oncology Therapeutics, BBOT, PIPE, Trust Account, redemption, liquidation, going concern, Helix Acquisition Corp II